Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alza Delivery Technologies Reduce Drug Enhancement Costs To $80 Mil.

Executive Summary

Alza drug delivery technologies reduce the cost of developing an enhanced version of an already-marketed drug to $70 mil.-$80 mil., Alza Chairman Sam Saks, MD, said during Johnson & Johnson's business review Sept. 23

You may also be interested in...



Lilly cashes out on dapoxetine

PPD will acquire patents to the premature ejaculation product dapoxetine from Lilly for $65 mil. Lilly will also receive 5% royalties on annual sales greater than $800 mil. The renegotiation of the development deal allows PPD to receive full royalties and milestones from Johnson & Johnson, where the product is in Phase III trials. Alza licensed dapoxetine from PPD prior to its merger with J&J (1"The Pink Sheet" Sept. 30, 2002, p. 29)...

Lilly cashes out on dapoxetine

PPD will acquire patents to the premature ejaculation product dapoxetine from Lilly for $65 mil. Lilly will also receive 5% royalties on annual sales greater than $800 mil. The renegotiation of the development deal allows PPD to receive full royalties and milestones from Johnson & Johnson, where the product is in Phase III trials. Alza licensed dapoxetine from PPD prior to its merger with J&J (1"The Pink Sheet" Sept. 30, 2002, p. 29)...

Tufts R&D Cost Estimate Puts Cash Outlay At $403 Mil. Per NCE

The cash outlay required to complete development of a new chemical entity has increased to an average of more than $400 mil., the Tufts Center for the Study of Drug Development says

Related Content

UsernamePublicRestriction

Register

PS040527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel